The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

“As a company driven by science and patient-centricity, AstraZeneca stands in full support of this ... He said he hoped that ...

AstraZeneca's Dato-DXd faces challenges in overall survival data but holds potential for approval with promising PFS benefits ...

London-listed AstraZeneca shares fell more than 5% on Tuesday after results from the company's lung cancer trials showed that ...

An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...

AstraZeneca is continuing to study AZD8205 as a monotherapy in dose optimization expansion cohorts of patients with ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in ...

Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank. The ...

A Phase 3 trial found AstraZeneca's experimental lung cancer drug did not significantly improve patients' overall survival rates.

AstraZeneca's lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for ...